



Over two decades ago, Amidon et al. proposed a Biopharmaceutics Drug Classification scheme for correlating in vitro drug product dissolution and in 
vivo bioavailability based on recognizing drug dissolution 
and intestinal permeability are the fundamental 
parameters controlling rate and extent of absorption (1). 
Considering this Biopharmaceutics Classification System 
(BCS), drugs are classified into four classes, where Class 
3 drugs correspond to active pharmaceutical ingredients 
(APIs) with high aqueous solubility and low permeability 
(1). Of 123 oral drugs in immediate-release (IR) dosage 
forms on the World Health Organization (WHO) Essential 
Model List provisionally classified into BCS classes, the 
majority (around 34% to 38%) belong to Class 3 (2, 3).
For products to be interchangeable, the WHO states 
the products must be therapeutically equivalent, which 
includes pharmaceutical equivalence or alternative 
formulations with equivalent dosage forms, similar dose, 
route of administration, indications, and directions for 
usage, labeling, efficacy, safety, and bioequivalence to 
the comparator (4). In this framework, the BCS serves 
as a tool to identify compounds eligible for biowaiver, 
which implies that in vivo proof of bioequivalence may 
be replaced by in vitro dissolution studies comparing 
test and reference product (5, 6). The dissolution test, 
at first exclusively a quality control test, is now emerging 
as a surrogate equivalence test for certain categories of 
orally administered pharmaceutical products. For these 
products (typically solid oral dosage forms containing 
APIs with suitable properties), the similarity in in vitro 
dissolution profiles and excipient comparisons and risk–
benefit analysis can be used to document equivalence 
of a multisource product with a comparator product 
and waive in vivo bioequivalence testing (4). This BCS-
based biowaiver scheme has important advantages 
such as economic impact, time-saving, and avoidance of 
unnecessary testing in humans (3, 6). 
The regulations on BCS-based biowaivers were different 
between the WHO and the regulatory agencies US Food 
and Drug Administration (FDA) and European Medicines 
Agency (EMA) until 2015 (5). Currently, the FDA, EMA, and 
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WHO agree to allow BCS biowaivers both for Class 1 and 
Class 3 drugs (4, 7‒9). Argentina adopted these guidelines 
and published their own guidance documents (10, 11). 
Furthermore, scientists had already recommended the 
biowaiver extension, and some even considered that BCS 
Class 3 drugs are more suitable for biowaiver than Class 1 
APIs (3, 12‒18).
The absorption of a Class 3 drug is limited by its permeability 
and is less dependent upon the formulation. Therefore, if 
the in vitro dissolution of a Class 3 drug product is rapid 
enough, under all physiological conditions, the variation 
is attributable to alterations of physiology and/or 
membrane permeability rather than dosage form factors 
(19). Besides, if the amount and nature of the excipients 
are not expected to affect bioavailability, in vivo behavior 
will be similar to an oral solution, and Class 1 criteria can 
be applied (19, 20). For Class 3 drugs, the excipients of 
the formulation may be more critical than those for Class 
1 drugs. For this reason, it is recommended that only 
excipients which have already appeared in products with 
a marketing authorization in an ICH or associated country 
are used, and types and amounts of excipients should be 
similar in the test and comparator product (5). Thus, the 
WHO, FDA, and EMA would grant BCS-based biowaivers 
for drug products containing BCS Class 3 drugs, if 'very 
rapid dissolution' is established (i.e., at least 85% dissolved 
in up to 15 minutes), and excipients are qualitatively the 
same and quantitatively very similar (4, 7‒9, 20, 21). 
Metoclopramide (MET) is a centrally acting anti-emetic 
and prokinetic agent widely used for the treatment of 
ileus, gastro-oesophageal reflux disease, dyspepsia, 
nausea, and vomiting during migraine or cancer therapy 
(2, 22, 23). The recommended dose for MET is 10 mg 
(hydrochloride, HCl), according to the WHO Model List 
of Essential Medicines (24). In the BCS framework, MET 
is conservatively assigned to Class 3, or a boundary Class 
1/3, depending on the reviewed literature (2, 22, 23). 
MET has a biowaiver recommendation if, according to the 
biowaiver monograph, (a) the test product contains only 
excipients also present in MET HCl containing IR solid oral 
drug products approved in ICH or associated countries, 
(b) in amounts in normal use in IR solid oral dosage forms, 
and (c) the test product and the comparator both comply 
with the criteria for ‘very rapidly dissolving’ (5, 23). In those 
cases, the risk to accept a bioinequivalent drug product 
is extremely low, and if a bioinequivalent product passes 
the evaluation, the consequences for the patient will not 
be serious (5, 23). Moreover, in these cases where 85% of 
the labeled amount is dissolved within 15 minutes (for the 
test and reference products in all media), the similarity 
of dissolution profiles may be accepted as demonstrated 
without any mathematical evaluation (i.e., f2 calculation) 
(4, 8, 9, 25, 26). 
This research aimed to evaluate critical quality 
parameters, compare the dissolution profiles, and 
assess pharmaceutical equivalence and similarity of five 




MET exists as a base, as a monohydrochloride, and as a 
dihydrochloride (23). Both the European Pharmacopoeia 
and the United States Pharmacopeia (USP) use 
the name ‘metoclopramide hydrochloride’ for the 
monohydrochloride monohydrate (23). The MET HCl 
monohydrate bulk drug for our study (100.49% purity, on 
dried base) was purchased from Saporiti (Buenos Aires, 
Argentina). Five solid oral IR dosage forms (Samples A to 
E), were acquired from the pharmacies of Bahía Blanca 
city (Argentina). Sample D was the reference product; the 
other samples were multisource products. All tests were 
performed within product expiration dates (which were 
similar among samples). The information of the evaluated 
products is shown in Table 1. As MET is classified as a 
BCS Class 3 drug, the composition of excipients must be 
qualitatively the same and quantitatively very similar (9). 
A list of excipients is shown in Table 2.
Table 1. Evaluated Products
Sample API Content (mg)a Calculated METContent as Base (mg)
Price per
10 Tabletsb Storage Conditions
a
A MET dihydrochloride 10 mg 8.04 7.76 Between 15 and 30 oC
B MET (as HCl) 10 mg 10 5.60 Room conditions (preferably between 15 and 30 oC), protect from light
C MET (as HCl) 10 mg 10 5.64 Between 8 and 30 oC, in a fresh place in original container
D MET HCl (as monohydrate 10, 54 mg) 10 mg 8.92 5.85 Below 30 oC, protected from light
E MET dihydrochloride 10 mg 8.04 3.95 Room conditions, under 25 oC
aAs indicated on product label; bPrice in Argentinian Pesos, at the time of analysis. 
API, active pharmaceutical ingredient; MET, metoclopramide; HCl, hydrochloride
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Excipient typea                                 SampleExcipient A B C D (reference) E
Filler




celluloseb ------- ------- n/s ------- 30.290
Microcrystalline
celluloseb ------- n/s ------- 50.00 76.417
Disintegrant
Corn starchb 30.000 ------- ------- 30.00 -------
Povidone 6.000 n/s ------- ------- -------
Sodium starch
glycolate ------- n/s n/s 10.00 -------
Glidant
Talcb 1.750 n/s ------- 0.70 -------
Colloidal silicon
dioxideb ------- n/s ------- ------- -------





------- n/s(Ponceau 4R) -------
0.873 (Sunset 
yellow - Indigo 
carmine - 
Tartrazine)
TOTALc 130.0 ------- ------- 140.64 130.9
Hydrochloric acid, glacial acetic acid, potassium chloride, 
sodium acetate trihydrate, sodium hydroxide, and 
monobasic potassium phosphate analytical grade 
(Anedra, Argentina), and distilled water were used for 
assay and preparation of dissolution media. Buffer 
solutions including pH 1.2 hydrochloric acid buffer 
solution, pH 4.5 acetate buffer solution, and pH 6.8 
phosphate buffer solution were prepared according to 
USP (27).
Equipment
An Acculab ALC-210.4M electronic analytical balance 
(Acculab North America, USA) was used for weight 
measurements. The pH levels of the prepared buffer 
solutions were checked using an Altronix TPX-1 pH meter 
(Saen, Argentina). Tablet characteristics were evaluated 
using a Scout FGM02 friability tester, a Scout EGM02 
disintegration apparatus, and a Scout DGM02 hardness 
tester (Scout Electronic, Argentina). An Erweka DT60 
dissolution apparatus (Erweka GmbH, Germany) was 
used for dissolution testing of dosage forms. A Varian 
Cary 50Conc spectrophotometer (Varian Instruments, 
Australia) was used for assay and quantification of 
dissolved MET. An ultrasonic bath (Testlab, Argentina) 
was used for degassing of dissolution media.
Methods
Labels and patient information leaflets of all evaluated 
products were carefully examined to detect similarities 
and differences among the provided information (e.g., 
storage conditions) according to Argentine regulations 
(28, 29). Tablet friability (n = 10), hardness (n = 5), and 
disintegration tests (n = 6) were performed according 
to Farmacopea Argentina (FA) (29). MET assay and 
uniformity of dosage units (n = 10) were performed by 
ultraviolet spectrophotometry (29, 30). Dissolution tests 
were performed using a calibrated USP Apparatus 1 
(basket) at 50 rpm, and 900 mL of water as dissolution 
media (27, 29). Prior to testing, the dissolution media 
was preheated and degassed. Quality control dissolution 
tests (n = 6) were performed using distilled water at 
37.0 ± 0.5 °C as dissolution medium. Samples were 
withdrawn at 30 minutes, filtered through a 0.45-µm 
pore-size nylon membrane (Microclar, Argentina), and 
suitably diluted. Drug concentration was determined by 
spectrophotometric analysis at 308 nm, in triplicate, and 
compared with a MET calibration curve (R2 = 0.9995). 
Table 2. Qualitative and Quantitative Composition of Excipients
All values are expressed in mg. 
aList of ‘excipient type’ as specified in WHO Guidelines, for ‘quantitatively very similar’ evaluation (4); bThis excipient has multiple 
functions; cThis value includes the quantity of metoclopramide present in the formulation.
n/s, not specified (package, labels, patient information leaflets and/or literature).
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To assess similarity, dissolution profiles (n = 12) were 
performed at pH 1.2, 4.5, and 6.8 under the same 
experimental conditions of dissolution quality control 
test. Samples (10 mL each) were withdrawn at 5, 10, 15, 
20, 30, and 45 minutes, fresh medium was replaced, and 
samples were subsequently filtered, suitably diluted, and 
spectrophotometrically measured. The concentration 
in each sample was calculated from MET calibration 
curves constructed in each dissolution medium (R2 was 
between 0.9992 and 0.9999). Average cumulative drug-
release percentages were calculated for dissolution 
profile estimation. Each point of the dissolution profile 
corresponds to a mean value and its respective standard 
deviation.
Data Analysis
The generated analytical data was processed using a 
Microsoft Excel spreadsheet. The statistical evaluation 
of dissolution profiles was performed using analysis of 
variance (ANOVA) over dissolution efficiency (DE) values 
(31). DE is defined as the area under the dissolution curve 
up to a certain time, t, expressed as a percentage of the 
area of the rectangle described by 100% dissolution in 
the same time (32). In vitro equivalence between the 
reference and multisource products was established 
based on the acceptance criteria for similarity factor  f2 
(4, 7‒9).
RESULTS AND DISCUSSION
The USP requires MET tablets to contain an amount of 
MET HCl monohydrate equivalent to 90.0% to 110.0% of 
the labeled amount of MET base (27). FA also indicates 
that MET tablets should contain an amount of MET HCl 
equivalent to 90.0% to 110.0% of the labeled amount 
of MET base, and the WHO recommendation for oral 
administration ‘tablet, 10 mg (HCl)’ most probably 
means as anhydrous HCl (23, 29). As it was stated by 
Stosik et al. and noted in Table 1, the expression of the 
drug in marketed drug products was confusing (23). All 
evaluated products suggested the same strength, as a 
‘10’ accompanied their brand name, but, in fact, they 
contained different amounts of MET base (Table 1). 
This situation represents a typical problem in different 
countries and should be addressed by regulatory agencies. 
USP and FA specifications for packaging and storage 
indicate MET must be preserved in tight, light-resistant 
containers. Different criteria for the storage conditions 
are described in all evaluated products (Table 1). Some 
products (Samples A and B) specified more restricted 
temperature ranges than others (Samples C, D, and E), 
and only Samples B and D indicated protection from light. 
Standardization of the given information should also be 
addressed by regulatory agencies. 
For BCS Class 3 products biowaivers, the excipient 
composition of the test product must be qualitatively 
the same and quantitatively very similar to the 
reference product (4, 7). As a general rule, the closer the 
composition of the multisource product to that of the 
comparator product with regard to excipients, the lower 
the risk of an inappropriate decision on equivalence 
using a biowaiver based on the BCS (4). Nevertheless, the 
definition of ‘quantitatively very similar’ is stated in the 
WHO Guideline, which presents a table with the limits on 
the relative difference in the amount of excipient in two 
solid oral pharmaceutical products for the products to be 
considered ‘quantitatively similar’ in that excipient (4). 
This criterion seems to be difficult to apply in the case of 
excipients that serves multiple functions (e.g., cellulose, 
powdered; cellulose, microcrystalline; talc). 
The excipient compositions of evaluated samples 
are shown in Table 2. It is important to highlight the 
absence of excipients known to affect the absorption 
and bioavailability of APIs (e.g., mannitol, sorbitol, 
surfactants like sodium lauryl sulfate or polysorbates, 
polyethyleneglycol, and poloxamers, among others), 
which must be compulsorily declared for BCS Class 3 
drugs (4, 33). All evaluated formulations contained the 
same qualitative composition, in terms of excipient type, 
but did not have the same excipients. Besides, most 
excipients listed in Table 2 were present in MET solid 
oral IR dosage forms, with marketing authorizations 
in ICH or associated countries (23). With respect to the 
‘quantitatively very similar’ requirement, Samples B and C 
did not fulfill it, as they do not declare the amount of each 
excipient (Table 2). In the case of Sample A, the lubricant 
content difference (in terms of magnesium stearate) 
was higher than the limits specified by WHO Guidelines 
(4). Finally, in the case of Sample E, more information is 
needed on excipients that serves multiple functions to 
achieve relative differences determination and state an 
adequate conclusion.
Results of friability, hardness, disintegration time, assay, 
uniformity of dosage units, and dissolution tests are 
shown in Table 3. For friability tests, the specification 
states that ‘a maximum mean weight loss from the three 
samples of not more than 1.0% is considered acceptable 
for most products’ (27, 29). As it can be seen in Table 
3, all evaluated samples fulfilled the requirements for 
the friability test. On the other hand, because tablet 
hardness is not part of pharmacopoeia specifications, 
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and release limits are product-specific, the obtained 
results were considered acceptable  (Table 3).  For 
disintegration tests, the specification states ‘at the end 
of the time limit specified in the monograph, lift the 
basket from the fluid and observe the tablets: all of the 
tablets have disintegrated completely’ (27, 29). Although 
the MET tablets monograph did not state disintegration 
specifications, all samples completed their disintegration 
process within four minutes, which could be considered 
a suitable value (Table 3). Formulation A had the highest 
disintegration time, which corresponds with its higher 
lubricant content, as it is shown in Table 2 and discussed 
above. 
MET tablets should contain an amount equivalent to 
90.0% to 110.0% of the labeled amount of MET base 
(27, 29). Assay results for all evaluated products were 
between those limits (i.e., the formulations fulfilled the 
assay requirements, see Table 3). Finally, the uniformity 
of dosage unit specifications indicates that API content 
should be between 85.0% to 115.0% of the labeled 
amount in each evaluated dosage unit, and the relative 
standard deviation should not exceed 6.0% (27, 29). 
As noted in Table 3, all evaluated products fulfilled the 
requirements for uniformity of dosage units test, and 
content uniformity results were in agreement with weight 
variation results (where Samples C and D, with higher 
variability in uniformity of dosage units test, correspond 
with the same behavior in tablet weight comparison). 
The MET tablets monograph includes specifications for 
dissolution testing, stating ‘not less than 75% (Q) of the 
labeled amount of MET is dissolved in 30 minutes’ (27, 29). 
According to the results presented in Table 3, reference 
formulation D did not fulfill the dissolution test in Stage 
1 (27, 29). Nevertheless, it fulfilled the acceptance criteria 
for Stage 2 (data not shown). 
Figure 1 shows the dissolution profiles at pH 1.2, 4.5, and 
6.8. All formulations reached a plateau of approximately 
100% of MET dissolved at 45 minutes, with the exception 
of Sample E at pH 1.2, which exhibited a maximum of 85% 
dissolution. The highest dissolution rate corresponded 
to Samples B and E in all media. Formulation A showed 
the lowest dissolution rate at all evaluated media and 
reached the dissolution plateau at about 20 or 30 minutes 
of dissolution study. However, all other samples reached 
the plateau at earlier sampling points in all media. Sample 
A did not fulfill the ‘quantitatively similar’ requirement 
for lubricant content (Table 2), and magnesium stearate 
is hydrophobic and may retard the dissolution of a drug 
in a solid IR dosage form (34). Formulations B, C, D, and E 
were ‘very rapidly dissolving,’ in the three media (Fig. 1). 
On the other hand, Sample A was ‘rapidly dissolving’ (i.e., 
more than 85% of the labeled amount dissolved within 
30 minutes) in all dissolution media, so it could not be 
considered for biowaiver estimation because it did not 
fulfill the ‘very rapid dissolution’ criteria required for Class 
3 drugs (Fig. 1). 
MET dissolution was also assessed through statistical 
comparison of profiles in terms of DE. As noted in Figure 2, 
Samples B and E exhibited a higher DE performance than 
the reference in almost all conditions. Formulation C was 
the only sample that did not show statistical differences 
with the reference formulation in all evaluated media. In 
contrast, the only sample that was significantly different 















A 0.00 8.0 ± 0.8 235 131.0 ± 0.7 98.6 ± 0.9 [99.2–100.5] / 1.1 [91–92] / 0.7
B 0.04 3.3 ± 0.6 143 101.4 ± 0.1 96.8 ± 1.6 [96.3–99.6] / 1.2 [84–93] / 3.2
C 0.15 4.5 ± 0.4 161 200.4 ± 4.7 100.5 ± 2.5 [97.3–106.2] / 3.4 [85–91] / 2.4
D 0.16 3.4 ± 0.2 118 140.5 ± 2.5 95.3 ± 1.7 [94.3–102.7] / 3.7 [79–84] / 1.9
E 0.02 5.0 ± 0.4 15 132.3 ± 0.6 98.5 ± 0.8 [97.3–99.7] / 1.0 [85–94] / 3.6
Table 3. Critical Quality Attributes Evaluation Results
aPercentage of weight loss; bMean ± SD; cMaximum time needed for complete disintegration of all evaluated tablets; dPercentage of 
labeled amount; e[range] of labeled amount / RSD; f[range] of labeled amount dissolved / RSD.
kp, kilopond, SD, standard deviation; RSD, relative SD.
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formulation A, with lower DE values in all cases. 
Finally, in a biowaiver scenario, dissolution profiles need 
to be compared in terms of similarity factor f2. However, 
as the reference and many of the test formulations (B, C, 
and E) showed a ‘very rapidly dissolution’ behavior, the 
profile similarity could be concluded as such without 
further mathematical comparison (4, 7). Nevertheless, 
to declare the interchangeability of these formulations, 
special consideration must be made regarding excipients 
composition issue (Table 2). Only formulation A could 
not be included in the similarity estimation because 
it did not fulfill the ‘very rapidly dissolution’ condition 
requested for Class 3 biowaivers or the ‘quantitatively 
similar amount of excipient’ criteria for lubricant content 
(Table 2). This formulation also had the highest hardness 
and disintegration time values (Table 3) and was the most 
expensive sample (Table 1). 
CONCLUSION
All evaluated formulations could be considered 
pharmaceutical equivalents because they fulfilled critical 
quality properties (i.e., tablet mechanical properties, 
assay, disintegration, and dissolution tests). In a biowaiver 
scenario, formulations B, C, and E could be considered 
essentially similar to the reference, as they fulfilled the 
‘very rapidly dissolving’ requirement for BCS Class 3 drugs. 
However, it is important to have access to the quantitative 
excipient composition (Samples B and C) and greater 
precision to establish reliable results on ‘quantitatively 
very similar’ determination (Sample E) to assure a safe 
interchangeability process for the present study. Only 
formulation A could not be declared interchangeable 
with the reference because it did not fulfill the ‘very 
rapidly dissolution’ or the ‘quantitatively similar amount 
of excipient’ criteria as required for Class 3 biowaivers. 
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Figure 1. Dissolution profiles for similarity evaluation at pH 1.2, 4.5, and 
6.8. Each point on the curve represents a mean value (n = 12) and its 
respective standard deviation (SD). Dotted line marks 85% dissolved 
(of labeled amount) level.
Figure 2. DE values at pH 1.2, 4.5, and 6.8 dissolution media. Each bar 
represents a mean value (n=12) and its respective standard deviation 
(SD). DE is defined as the area under the dissolution curve up to a 
certain time, t, expressed as a percentage of the area of the rectangle 
described by 100% dissolution in the same time (32).
*: Significant statistical differences were found between the multisource 
formulation and the reference sample, D (p<0.05)
**: Highly significant statistical differences were found betweenthe 
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